Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway by Hayami, Shinya et al.
RESEARCH Open Access
Overexpression of the JmjC histone demethylase
KDM5B in human carcinogenesis: involvement in
the proliferation of cancer cells through the E2F/
RB pathway
Shinya Hayami
1,2, Masanori Yoshimatsu
1, Abhimanyu Veerakumarasivam
3,4, Motoko Unoki
5, Yukiko Iwai
1,
Tatsuhiko Tsunoda
6, Helen I Field
7, John D Kelly
3,8, David E Neal
3, Hiroki Yamaue
2, Bruce AJ Ponder
3,
Yusuke Nakamura
1*, Ryuji Hamamoto
1,3
Abstract
Background: Although an increasing number of histone demethylases have been identified and biochemically
characterized, their biological functions largely remain uncharacterized, particularly in the context of human
diseases such as cancer. We investigated the role of KDM5B, a JmjC histone demethylase, in human carcinogenesis.
Quantitative RT-PCR and microarray analyses were used to examine the expression profiles of histone demethylases
in clinical tissue samples. We also examined the functional effects of KDM5B on the growth of cancer cell lines
treated with small interfering RNAs (siRNAs). Downstream genes and signal cascades induced by KDM5B expression
were identified from Affymetrix Gene Chip experiments, and validated by real-time PCR and reporter assays. Cell
cycle-dependent characteristics of KDM5B were identified by immunofluorescence and FACS.
Results: Quantitative RT-PCR analysis confirmed that expression levels of KDM5B are significantly higher in human
bladder cancer tissues than in their corresponding non-neoplastic bladder tissues (P < 0.0001). The expression
profile analysis of clinical tissues also revealed up-regulation of KDM5B in various kinds of malignancies.
Transfection of KDM5B-specific siRNA into various bladder and lung cancer cell lines significantly suppressed the
proliferation of cancer cells and increased the number of cells in sub-G1 phase. Microarray expression analysis
indicated that E2F1 and E2F2 are downstream genes in the KDM5B pathway.
Conclusions: Inhibition of KDM5B may affect apoptosis and reduce growth of cancer cells. Further studies will
explore the pan-cancer therapeutic potential of KDM5B inhibition.
Background
Histone methylation plays an important dynamic role in
regulating chromatin structure. Precise coordination and
organization of open and closed chromatins are crucial
for normal cellular processes such as DNA replication,
repair, recombination and transcription. Until recently,
histone methylation was considered to be a static modi-
fication, but the identification of histone demethylases
has revealed that this modification is dynamically
regulated [1,2]. Histone demethylases regulate not only
the modification itself but also its extended function,
by antagonizing the binding of effector proteins to mod-
ified chromatin. This is exemplified by JHDM3A/
JMJD2A, which displaces HP1 from chromatin by
demethylating the H3K9 methylation and thereby pre-
venting the spread of H3K9 methylation to the sur-
rounding chromatin by HP1 [3,4]. A highly-conserved
family of proteins containing the JmjC domain was
recently characterized to possess a histone demethylase
activity [5]. Despite a large body of information for the
prominent role of histone demethylases in transcrip-
tional regulation, their physiological function, and their
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understood.
We previously reported that SMYD3, a histone
methyltransferase, stimulates cell proliferation through
its methyltransferase activity and plays a crucial role in
human carcinogenesis [6-10]. Although dysfunction of
histone methylation status was indicated to contribute
to human carcinogenesis [11-13], the relationship
between abnormal histone demethylation and human
carcinogenesis is still largely unclear.
In order to find demethylases that contribute to
human carcinogenesis, we examined the expression pro-
files of several proteins containing a JmjC histone
demethylase domain in clinical tissues and found that
expression levels of KDM5B were significantly up-regu-
lated, compared with their corresponding normal tis-
sues, in many types of cancer.
KDM5B, also named JARID1B or PLU-1, is one of the
four JARID family members [14,15], and contains
domains common to transcriptional regulators such as a
JmjN domain, a Bright/Arid domain, a C5H2C zinc fin-
ger motif, and several PHD domains in addition to a
JmjC domain. All four members of the JARID family
possess the H3K4 demethylase activity [16-20]. Each
member might participate in different biological pro-
cesses through recruitment to different chromosomal
regions and differing enzymatic activities [5]. Here we
demonstrate a novel function of KDM5B in human car-
cinogenesis and show that it is related to the cell cycle
through regulation of E2F expression and cell growth.
Results
KDM5B expression is up-regulated in clinical cancer
tissues
We first examined expression levels of five jumonji his-
tone demethylase genes included in JARID family,
KDM5A (JARID1A), KDM5B (JARID1B), KDM5C (JAR-
ID1C), KDM5D (JARID1D) and JARID2, in a small sub-
set of clinical bladder cancer samples and found a
significant difference in expression levels between nor-
mal and cancer cells only for the KDM5B gene (data
not shown). Therefore, we analyzed 123 bladder cancer
samples and 23 normal control samples (British) and
confirmed significant elevation of KDM5B expression in
tumor cells compared with in normal cells (P < 0.0001,
Mann-Whitney’s U-test) (Figure 1A and Additional file
1). No significant difference was observed in expression
levels among different grades and stages (Table 1 and
Additional file 1). This suggests that KDM5B expression
was up-regulated in an early stage of bladder carcino-
genesis, and remained high in the advanced stages of
the disease. Subclassification of tumors according to
gender, smoking history, metastasis status, and recur-
rence status identified no significant difference in the
expression levels of KDM5B (Table 1). We then ana-
lyzed the expression patterns of KDM5B in a number of
clinical samples derived from Japanese bladder cancer
subjects examined by cDNA microarray (Figure 1B and
1C), and confirmed its significant overexpression (P <
0.0001, Mann-Whitney’s U-test).
To evaluate protein expression levels of KDM5B in
bladder tissues, we performed immunohistochemical
analysis using anti-KDM5B specific antibody (Figure
1D). We observed strong KDM5B staining mainly in the
nucleus of malignant cells, but no significant staining in
non-neoplastic tissues. To further validate this result, we
conducted tissue microarray experiments using 29 blad-
der tissue sections (Figure 2 and Additional file 2), and
observed strong staining in 6 cases, and weak or moder-
ate staining was observed in 13 cases. Moreover, no sig-
nificant relationship between KDM5B protein
expression levels and clinicopathologic characteristics
was detected, consistent with our real-time PCR results.
In addition to bladder tissues, we measured expression
levels of KDM5B in lung tissues (Figure 3 and 4). cDNA
microarray experiments showed that KDM5B expression
was also highly elevated in lung tumor tissues compared
with corresponding non-neoplastic tissues (Figure 3A-
D). Importantly, elevated KDM5B expression was
observed in both non-small cell lung cancers and small
cell lung cancers, indicating that KDM5B overexpression
is involved widely in lung carcinogenesis. We then
examined KDM5B protein expression levels in lung tis-
sue by immunohistochemistry (Figure 3E). We observed
strong KDM5B staining in cancer tissues and no signifi-
cant staining in non-neoplastic tissues. To evaluate pro-
tein expression levels of KDM5B in various types of
lung tumor tissues, we conducted tissue microarray
experiments (Figure 4 and Additional file 3). Among 62
tumor tissue sections examined, we observed strong
staining in 16 cases, and weak or moderate staining in
28 cases. In addition, we examined microarray expres-
sion analysis data of a large number of clinical samples
derived from Japanese subjects and found that KDM5B
expression was also significantly up-regulated in acute
myelogenous leukemia (AML), breast cancer, chronic
myelogenous leukemia (CML), cervical cancer and renal
cell carcinoma (RCC) compared with corresponding
non-neoplastic tissues, indicating its possible involve-
ment in many types of human cancer (see Additional
files 4 and 5).
Growth regulation of cancer cells by KDM5B
To investigate the role of KDM5B in human carcinogen-
esis, we performed a knockdown experiment using two
independent siRNAs against KDM5B (siKDM5B#1 and
#2) and two control siRNAs (siEGFP and siNC). We
transfected these siRNAs into SW780, A549 and SBC5
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tional file 6A). Expression levels of KDM5B in the cells
transfected with two independent siRNAs targeting
KDM5B were significantly suppressed, compared to
those transfected with control siRNAs (Figure 5A).
Using the same siRNAs, we performed cell growth
assays and found significant growth suppression by two
independent siRNAs targeting KDM5B for two bladder
cancer cell lines (SW780 and RT4) and three lung can-
cer cell lines (A549, LC319 and SBC5) while no effect
was observed when we used control siRNAs (Figure 5B).
To further assess the mechanism of growth suppression
induced by the siRNA, we analyzed the cell cycle status
of cancer cells after treatment with siRNAs using flow
cytometry (Figure 5C). The proportion of cancer cells at
the sub-G1 phase was significantly higher in the cells
treated with siKDM5B than those treated with control
siRNAs (P =0 . 0 0 5 5[ s i E G F P ,s i K D M 5 B ]a n dP =0 . 0 0 4 2
[siFFLuc, siKDM5B], respectively, Figure 5D). As
increasing the number of cells at sub-G1 phase has been
considered as a marker of apoptosis [21], it is possible
that apoptosis can be induced by knockdown of
KDM5B expression. We also performed BrdU and 7-
AAD staining analysis, and the data are concordant with
PI-staining FACS analysis (see Additional file 6B).
Identification of the downstream genes by microarray
expression analysis
We then performed microarray expression analysis to
identify signal pathways of downstream of KDM5B. In
Figure 1 Elevated KDM5B expression in bladder cancer in British and Japanese patients. (A) KDM5B gene expression in normal and tumor
bladder tissues in British cases. Expression levels of KDM5B were analyzed by quantitative real-time PCR, and the result is shown by box-whisker
plot (median 50% boxed). Relative mRNA expression shows the value normalized by GAPDH and SDH expressions. Mann-Whitney’s U-test was
used for statistical analysis. (B) Expression ratio between bladder normal and tumor tissues in Japanese patients. Signal intensity for each sample
was analyzed by cDNA microarray, and the expression ratio is the signal intensity in tumor divided by that in normal (1 is normal). (C)
Comparison of KDM5B expression between normal and tumor bladder tissues in Japanese patients. Signal intensity of each sample was analyzed
by cDNA microarray, and the result is shown by box-whisker plot (median 50% boxed). Mann-Whitney’s U-test was used for statistical analysis.
(D) Immunohistochemical staining of KDM5B in bladder tissues. Nonimmunized mouse IgG was used as a substitute for the primary antibody to
eliminate the possibility of false-positive responses from non-specific binding of IgG or from the secondary antibody. Counterstaining was done
with hematoxylin and eosin. Original magnification, ×40 and ×400.
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of KDM5B, we isolated total RNA from SW780 and
A549 cells, 24 hours after treatment with siKDM5B.
The expression profile analysis of these cells using Affy-
metrix HG-U133 Plus 2.0 Array in comparison with
those treated with control siRNAs (siEGFP and siFFLuc)
identified a set of genes significantly up/down-regulated.
We further performed a signal pathway analysis, refer-
ring to the Gene Ontology database (Methods and
Additional file 7), and found that KDM5B could be clo-
sely linked with the process of cell cycle regulation.
Interestingly, we observed significant down-regulation of
E2F1 and E2F2 by treatment with siKDM5B (P < 0.0001
for both) (see also Additional file 8). As the E2F/RB
pathway is a key regulator of the cell cycle, we analyzed
the functional relationship between KDM5B expression
and this pathway.
We confirmed the down-regulation of E2F1 and E2F2
expression in three different cancer cell lines, SW780,
A549 and SBC5 treated with siRNAs, by quantitative
r e a l - t i m eP C R( F i g u r e6 Aa n d6 B ) .M o r e o v e r ,w ea l s o
found higher expression levels of both E2F1 and E2F2
in clinical tumor tissues where KDM5B was overex-
pressed, than in non-neoplastic tissues (P = 0.0009 and
P =0 . 0 0 0 2 ,r e s p e c t i v e l y ) .T h ed a t ai n d i c a t et h a tb o t h
E2F1 and E2F2 could be highly expressed in tumor tis-
sues correlating with elevated expression of KDM5B
(Spearman’s rank correlation coefficient: r = 0.666
[E2F1] and r = 0.756 [E2F2], respectively) (Figure 6C).
To validate the transcriptional regulation of E2F by
KDM5B in more detail, we performed luciferase repor-
ter assays using an E2F-responsive luciferase construct
(Figure 6D). We transfected the construct into cancer
cell lines after treatment with siEGFP or siKDM5B. The
E2F-driven transcriptional activity was significantly sup-
pressed after treatment with siKDM5B in both A549
and SBC5 cells. Furthermore, we also confirmed sup-
pression of both E2F1 and E2F2 expressions in A549
and SBC5 cells at the protein level after treatment with
two independent siRNAs targeting KDM5B (Figure 6E).
These results reveal that the transcriptional activity
regulated by E2F transcription factors can be suppressed
after knockdown of KDM5B, and this disruption of this
pathway may be responsible for the cell cycle alterations
which we have observed.
Discussion
Histone modifications of chromatin, including methyla-
tion, acetylation, phosphorylation and ubiquitination,
play a critical role in creating transcriptional activation
and repression patterns, through the regulation of chro-
matin structure. KDM5B belongs to the lysine demethy-
lase family, which specifically removes the methyl group
o fh i s t o n eH 3l y s i n e4[ 2 0 ] .I nt h i ss t u d y ,w ed e m o n -
strated the significant up-regulation of KDM5B in blad-
der and lung cancers as well as various other cancer
types, using quantitative RT-PCR, immunohistochemis-
try, and microarray-based gene expression profiles. Con-
sistently with reports from other groups [20,22], we
showed that KDM5B expression is dysregulated in a
great majority of human tumors. We previously
reported the copy number gain at a region of chromo-
some 1q32.1 (200963156-201045186), where the
KDM5B gene is located, in 17 of 98 bladder tumors
(British cases) [23]. We found that the clone RP11-
203F10 (200861805-201051225) used for this tile-path
array analysis included an entire KDM5B gene.
Although most of the cases were considered to be trans-
activated by other mechanisms, including epigenetic
changes or activation of factors regulating the KDM5B
transcription, the copy number gain in nearly 20% of
the cases indicated some significances of this copy num-
ber gain in bladder carcinogenesis.
KDM5B expression is very low in normal tissues other
than adult testis [24], and we observed no significant
KDM5B staining in vital organs by immunohistochem-
ical analysis (Figure 1D, 3E and Additional file 9).
Therefore, aberrant overexpression of KDM5B in any
tumor, compared to corresponding non-neoplastic tis-
sues, make it an ideal molecular target with potential for
cancer detection and as a therapeutic target. Already,
Table 1 Statistical analysis of KDM5B expression levels in
clinical bladder tissues
KDM5B expression
Factor n Mean SD 95%CI
Normal (Control) 23 1.935 0.549 1.698 - 2.173
Tumor (Total) 123 5.018 3.322 4.425 - 5.611
Gender
Male 90 5.032 3.378 4.324 - 5.739
Female 31 4.477 2.243 3.654 - 5.299
Smoke
No 27 4.702 2.246 3.813 - 5.590
Yes 49 5.549 4.050 4.386 - 6.712
Grade
G1 12 5.035 2.654 3.349 - 6.720
G2 62 5.740 3.982 4.728 - 6.751
G3 48 4.079 2.196 3.441 - 4.717
Metastasis
Negative 96 4.988 3.547 4.269 - 5.706
Positive 27 5.125 2.408 4.173 - 6.078
Recurrence
No 27 5.606 4.735 3.733 - 7.480
Yes 50 4.988 2.540 4.266 - 5.710
Died 8 5.948 3.280 3.205 - 8.690
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used as tools in epigenetic studies, and many have
shown growth-suppressive effects in cancer cells in vitro
and have been used in early phase clinical trials [25,26].
In addition, some histone methyltransferase and
demethylase inhibitors have recently been reported
[27-29]. Further functional studies of KDM5B will pro-
vide useful information for development of demethylase
inhibitors that might show a great promise as a new
type of molecular targeted-cancer drugs, as well as
HDAC inhibitors.
We demonstrated that E2F1 and E2F2 are candidate
downstream modulators regulated by KDM5B. A lucifer-
ase reporter assay, combined with siRNA treatment,
yielded indirect evidence supporting a molecular inter-
action between KDM5B and E2F elements. The E2F
transcription factors are downstream effectors of the
retinoblastoma (RB) protein pathway and are involved
in many aspects of fundamental cell cycle control
[30-33]. Binding sites for E2F factors have been identi-
fied in a large number of genes that control cell cycle
and DNA synthesis, including cdk2 and 4, cyclin A, D
and E, DNA polymerase, ribonucleotide reductase,
UHRF1 and PCNA [34,35]. Importantly, mutations in
the RB-E2F cascade are found in a wide range of tumor
types [36,37]. Most of these alterations affect RB or
upstream regulators of E2F transcriptional factors, and
there is growing evidence that dysregulation of the E2F
family itself is crucially involved in carcinogenesis.
Indeed, in ovarian cancer, the proliferation-promoting
E2F1 and E2F2 transcription factors were overexpressed,
compared with healthy control tissues [38]. Their dysre-
gulation has been proposed as a prognostic indicator for
various tumors [39-43]. Overexpression of a prolifera-
tion-promoting E2F transcription factor is argued to
contribute a significant growth advantage to tumors
especially those with poor prognosis. In the present
study, we demonstrated significantly higher expression
of both E2F1 and E2F2 in bladder tumor tissues than in
non-neoplastic tissues, which are probably due to aber-
rant transcriptional regulation of KDM5B. Detailed
pathway analysis on the basis of Gene Ontology revealed
Figure 2 Tissue microarray images of bladder tumors stained by standard immunohistochemistry for protein expression of KDM5B.
Clinical information for each section is represented above histological pictures. Counterstaining was done with hematoxylin and eosin. Original
magnification, ×100, ×200 and ×400.
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cesses (see also Additional file 7).
According to our microarray data, a number of other
genes could be up-regulated by KDM5B. One of
KDM5B’s main functions was considered to be tran-
scriptional repression through its demethylase activity
because H3K4 methylation is a marker for euchromatin
[20]. From our microarray data, we propose three possi-
ble mechanisms whereby KDM5B can activate the tran-
scription of its downstream genes. (i) Transcription is
indirectly activated through transcription factors that
are directly regulated by KDM5B; (ii) KDM5B transacti-
vates expression of downstream candidates through pro-
tein-protein interaction. For example, KDM5B associates
with the androgen receptor and enhances its transcrip-
tional activity [22]. KDM5B might both up- and down-
regulate gene expressions, depending on its binding
partners. (iii) KDM5B demethylates unknown substrates.
Similarly, LSD1 was first reported to be a H3K4 specific
demethylase [1], and later found to demethylate histone
H3 lysine 9 and p53 [44,45]. Interestingly, in this study,
we found that KDM5B was localized in the cytoplasm at
some cell-cycle phases (see Additional files 10 and 11),
raising the possibility that it might demethylate
unknown substrates in the cytoplasm and then affect
cell cycle progression. Furthermore, Xiang et al has
shown that there may be a correlation between KDM5B
expression and the stage of prostate cancer [22] and
Yamane et al reported that KDM5B knockdown
increased G1 phase of MCF7 cells [20]. While these are
some discrepancies between our current result and the
previous reports, these differences may reflect the differ-
ent KDM5B roles in different tissues. However, our
results using several cancer cell lines strongly support
Figure 3 Elevated KDM5B expression in lung cancer. (A and B) Expression ratio between normal lung and tumor (non-small cell lung cancer
[NSCLC] in A and small cell lung cancer [SCLC] in B) lung tissues in Japanese patients. Signal intensity for each sample was analyzed by cDNA
microarray, and the expression ratio is the signal intensity in tumor divided by that in normal (1 is normal). (C and D) Comparison of KDM5B
expression between normal and tumor (NSCLC and SCLC) lung tissues. Signal intensity of each sample was analyzed by cDNA microarray, and
the result is shown by box-whisker plot (median 50% boxed). Mann-Whitney’s U-test was used for the statistical analysis. (E)
Immunohistochemical staining of KDM5B in lung tissues. Nonimmunized mouse IgG was used as a substitute for the primary antibody to verify
the possibility of false-positive responses from non-specific binding of IgG or from the secondary antibody. Counterstaining was done with
hematoxylin and eosin. Original magnification, ×40 and ×400.
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cancer cells.
Conclusions
The present study identified high expression of KDM5B,
a JmjC histone demethylase, in the majority of bladder
tumor tissues analyzed by real-time PCR. Microarray
data indicated significantly higher levels of KDM5B
expression in many types of tumor tissues compared to
corresponding non-neoplast i ct i s s u e s .W es h o w e dt h a t
reduction of KDM5B expression resulted in suppression
of cell growth of cancer cells, through co-regulation of
the E2F/RB1 cell cycle regulation pathway, and possibly
the promotion of apoptosis of cells remaining in sub-G1
phase. As significant high expression of KDM5B was
only observed in cancer cells, and its knockdown sup-
pressed the growth of cancer cells, it may be an ideal
druggable molecular target. Further functional analyses
of this protein could contribute to development of
novel therapeutic strateg i e sf o rb l a d d e ra n do t h e r
carcinomas.
Materials and methods
Tissue samples and RNA preparation
123 surgical specimens of primary urothelial carcinoma
were collected, either at cystectomy or transurethral
resection of bladder tumor (TUR-Bt), and snap-frozen
in liquid nitrogen. 23 normal bladder tissues were col-
lected from areas of macroscopically-normal regions in
patients with no evidence of malignancy. Use of tissues
for this study was approved by Cambridgeshire Local
Research Ethics Committee (Ref 03/018). A total of
thirty 30-μm sections were homogenized for RNA
extraction and two 7-μm ‘sandwich’ sections adjacent to
the tissue used for RNA extraction were sectioned,
stained and assessed for cellularity and tumor grade by
an independent consultant urohistopathologist. Addi-
tionally, the sections were graded according to the
degree of inflammatory cell infiltration (low, moderate
and significant). Samples showing significant inflamma-
tory cell infiltration were excluded [46].
Total RNA was extracted using TRI Reagent™ (Sigma,
Dorset, UK), following the manufacturer’sp r o t o c o l .
Figure 4 Tissue microarray images of lung tumors stained by standard immunohistochemistry for protein expression of KDM5B.
Clinical information for each section is represented above histological pictures. Counterstaining was done with hematoxylin and eosin. Original
magnification, ×100, ×200 and ×400.
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Page 7 of 14RNeasy Mini Kit™ (QIAGEN, Crawley, UK), including a
DNase step, was used to optimize RNA purity. Agilent
2100™ total RNA bioanalysis was performed. 1 μl of resus-
pended RNA from each sample was applied to an RNA
6000 Nano LabChip™ and processed according to the
manufacturer’s instructions. All chips and reagents were
sourced from Agilent Technologies™ (West Lothian, UK).
Reverse transcription
Total RNA concentrations were determined using the
NanoDrop™ ND1000 spectrophotometer (Nyxor Biotech,
Paris, France). 1 μg of total RNA was reversely transcribed
with 2 μg of random hexamers (Amersham) and Super-
script III reverse transcriptase (Invitrogen, Paisley, UK) in
20 μl reactions according to the manufacturer’si n s t r u c -
tions. cDNA was then diluted 1:100 with PCR grade water
and stored at -20°C.
Laser capture microdissection
Tissue for laser capture microdissection was collected
prospectively following the procedure outlined above.
Five sequential sections of 7-μmt h i c k n e s sw e r ec u t
from each tissue and stained using HistoGene™ staining
solution (Arcturus, California, USA) following the
Figure 5 Involvement of KDM5B in the growth of bladder and lung cancer cells. (A) Quantitative real-time PCR showing suppression of
endogenous expression of KDM5B by two KDM5B-specific siRNAs (siKDM5B#1 and #2) in SW780, A549 and SBC5 cells. siEGFP and siNC were
used as controls. mRNA expression levels were normalized by GAPDH and SDH expressions, and values are relative to siEGFP (siEGFP = 1). Results
are the mean ± SD of three independent experiments. P-values were calculated using Student’s t-test (**, P < 0.01; ***, P < 0.001). (B) Effect of
KDM5B siRNA knockdown on the viability of bladder cancer cell lines (RT4 and SW780) and lung cancer cell lines (A549, LC319 and SBC5).
Relative cell number shows the value normalized to siEGFP-treated cells. Results are the mean ± SD in three independent experiments. P-values
were calculated using Student’s t-test (*, P < 0.05; **, P < 0.01; ***, P < 0.001). (C) DNA content of SBC5 cells analyzed by FACS 72 hours after the
treatment with control siRNAs and siKDM5B#1. We show representative histograms for each experiment. (D) Numerical analysis of the FACS
results in C, classifying cells by cell cycle status. The proportion of cancer cells in sub-G1 phase is significantly high after treatment with siKDM5B
compared to control siRNAs-treated cancer cells. Results are the mean ± SD in three independent experiments. P-values were calculated using
Student’s t-test (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
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Page 8 of 14manufacturer’s protocol. Slides were then immediately
transferred for microdissection using a PixCell II laser
capture microscope™ (Arcturus, California, USA). This
technique employs a low-power infrared laser to melt a
thermoplastic film over the cells of interest, to which
the cells become attached.
Approximately 10,000 cells were microdissected from
both stromal and epithelial/tumor compartments in
each tissue. RNA was extracted using an RNeasy Micro
Kit™ (QIAGEN, Crawley, UK). Areas of cancer or stroma
containing significant inflammatory areas of tumor or
stroma containing significant inflammatory cell infiltra-
tion were avoided to prevent contamination.
Total RNA was reversely transcribed and qRT-PCR
was performed as shown above. Given the low yield of
RNA from such small samples, NanoDrop™ quantifica-
tion was not performed, but correction for the endogen-
ous 18S CT value was used as an accurate measure of
the amount of intact starting RNA. Transcript analysis
was performed for the KDM5B genes.
To validate the accuracy of microdissection, qRT-PCR
using primers and probes for Vimentin and Uroplakin
were performed according to the manufacturer’s instruc-
tions (Assays on demand, Applied Biosystems, Warring-
ton, UK). Vimentin is primarily expressed in
mesenchymal tissue, and was used as a stromal marker.
Figure 6 Confirmation of E2F1 and E2F2 as downstream genes of KDM5B. (A and B) Expression levels of E2F1 (A) and E2F2 (B) in SW780,
A549 and SBC5 cells were analyzed by real-time PCR after treatment with siRNAs targeting KDM5B (siKDM5B) and EGFP (control; siEGFP = 1).
Relative mRNA expression is an arbitrary value, but for each cell population, expression was normalized to GAPDH and SDH expressions. Statistical
analysis was based on nine independent experiments. P-values were calculated using Student’s t-test. (C) E2F1 and E2F2 expressions as measured
by real-time PCR were significantly up-regulated in bladder tumor tissues compared to non-neoplastic bladder tissues, in proportion to that of
KDM5B expression in tumor tissue. We analyzed 13 cancer and normal tissues, and Spearman’s rank correlation coefficient was used for the
statistical analysis. (D) Knockdown of KDM5B expression repressed the transcriptional activity of E2F. Results are the mean ± SD in three
independent experiments. P-values were calculated using Student’s t-test. (E) Validation of KDM5B and E2F1 expressions at the protein level.
Lysates from A549 and SBC5 cells after both siKDM5B#1 and siKDM5B#2 treatments were immunoblotted with anti-KDM5B, E2F1, E2F2 and actin
antibodies. Expression of actin served as an internal control.
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served in up to 90% of epithelially-derived cells [47].
Cell culture
All cell lines were grown in monolayers in appropriate
media: Dulbecco’s modified Eagle’s medium (D-MEM)
for EJ28 bladder cancer cells and RERF-LC-AI non-small
cell lung cancer cells; Eagle’s minimal essential medium
(E-MEM) for 253J, 253J-BV, HT1197, HT1376, J82, SCa-
BER, UMUC3 bladder cancer cells and SBC5 small cell
lung cancer cells; Leibovitz’s L-15 for SW780 cells;
McCoy’s5 Am e d i u mf o rR T 4a n dT 2 4b l a d d e rc a n c e r
cells; RPMI1640 medium for 5637 bladder cancer cells
and A549, H2170 and LC319 non-small cell lung cancer
cells supplemented with 10% fetal bovine serum and 1%
antibiotic/antimycotic solution (Sigma). All cells were
maintained at 37°C in humid air with 5% CO2 condition
(5637, 253J, 253J-BV, EJ28, HT1197, HT1376, J82, RT4,
SCaBER, T24, UMUC3, A549, H2170, LC319, RERF-LC-
AI and SBC5) or without CO2 (SW780). Cells were trans-
fected with FuGENE6™ (Roche Applied Science, Basel,
Switzerland) according to manufacturer’s protocols.
Expression profiling in cancers using cDNA microarrays
We established a genome-wide cDNA microarray with
36,864 cDNAs or ESTs selected from the UniGene data-
base of the National Center for Biotechnology Informa-
tion (NCBI). This microarray system was constructed
essentially as described previously [48-50]. Briefly, the
cDNAs were amplified by RT-PCR using poly (A)
+ RNAs
isolated from various human organs as templates; the
lengths of the amplicons ranged from 200 to 1,100 bp,
without any repetitive or poly (A) sequences. Many types
of tumors and corresponding non- neoplastic tissues
were prepared in 8-μm sections, as described previously
[49]. A total of 30,000-40,000 cancer or noncancerous
cells were collected selectively using the EZ cut system
(SL Microtest GmbH, Germany) according to the manu-
facturer’s protocol. Extraction of total RNA, T7-based
amplification, and labeling of probes were performed as
described previously [49]. 2.5-μg aliquots of twice-ampli-
fied RNA (aRNA) from each cancerous and noncancer-
ous tissue were then labeled, respectively, with Cy3-
dCTP or Cy5-dCTP. Detailed expression profiling data of
bladder and lung cancers, shown in this study, were
based on the data reported previously by Drs. Ryo Takata
and Takefumi Kikuchi, respectively [48,51].
Quantitative real-time PCR
As described above, we obtained 123 bladder cancer tis-
sues and 23 normal bladder tissues in Cambridge
Addenbrooke’s Hospital. For quantitative RT-PCR reac-
tions, specific primers for all human GAPDH (house-
keeping gene), SDH (housekeeping gene) and KDM5B
were designed (primer sequences in Additional file 12).
PCR was performed using the ABI prism 7700 Sequence
Detection System (Applied Biosystems, Warrington, UK)
following the manufacturer’s protocol. 50% SYBR
GREEN universal PCR Master Mix without UNG
(Applied Biosystems, Warrington, UK), 50 nM each of
the forward and reverse primers and 2 μl of reversely-
transcribed cDNA were applied. Amplification condi-
tions were 5 min at 95°C and then 45 cycles each con-
sisting of 10 sec at 95°C, 1 min at 55°C and 10 sec at
72°C. Then, reactions were heated for 15 sec at 95°C,
1 min at 65°C to draw the melting curve, and cooled to
50°C for 10 sec. Reaction conditions for target gene
amplification were as described above and the equiva-
lent of 5 ng of reverse transcribed RNA was used in
each reaction. mRNA levels were normalized to GAPDH
and SDH expressions.
Immunohistochemical staining
Sections of human bladder and lung cancer were stained
by VECTASTAIN® ABC KIT (VECTOR LABORA-
TORIES, CA, USA). Briefly, endogenous peroxidase
activity of xylene-deparaffinized and dehydrated sections
was inhibited by treatment with 0.3% H2O2/methanol.
Non-specific binding was blocked by incubating sections
with 3% BSA in a humidified chamber for 30 min at
ambient temperature followed by overnight incubation
at 4°C with a 1:100 dilution of mouse monoclonal anti-
JARID1B (clone 1G10, Abnova) antibody. The sections
were washed twice with PBS (-), incubated with 5 μg/μl
goat anti-mouse biotinylated IgG in PBS (-) containing
1% BSA for 30 min at ambient temperature, and then
incubated with ABC reagent for 30 min. Specific immu-
nostaining was visualized by 3,3’-diaminobenzidine.
Slides were dehydrated through graded alcohol to xylene
washing and mounted on cover slips. Hematoxylin was
used for nuclear counterstaining. Bladder and lung
tumor tissue microarray slides were purchased from
BioChain Institute (Hayward, CA, USA).
Western blotting
Total protein extracts were prepared from the cells in
RIPA-like buffer. Total protein (50 μg) was transferred
to nitrocellulose membrane. The membrane was proved
with anti-JARID1B (clone 1G10, H00010765-M02,
Abnova or HPA027179, Atlas Antibodies AB), anti-E2F1
antibody (KH95, Santa Cruz Biotechnology) and anti-
E2F2 antibody (L-20, Santa Cruz Biotechnology). Anti-
Actin (I-19, Santa Cruz Biotechnology) was used as
loading control.
Transfection with small interfering RNAs
The small interfering RNA (siRNA) oligonucleotide
duplexes were purchased from SIGMA Genosys for
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FLuc and siNegative control (siNC), which is a mixture
of three different oligonucleotide duplexes, were used as
control siRNAs. The siRNA sequences are described in
Additional file 13. siRNA duplexes (100 nM final con-
centration) were transfected to bladder and lung cancer
cell lines with lipofectamine 2000 (Invitrogen) for 72
hours, and cell viability was examined using Cell Count-
ing Kit 8 (DOJINDO Laboratories).
Flow cytometry assays (FACS)
To examine the effect of KDM5B expression on the cell
cycle progression, SBC5 cells were treated with
siKDM5B or control siRNAs (siEGFP and siFFLuc), and
cultured in a CO2 incubator at 37°C for 72 hours. 1 ×
10
5 cells were collected by trypsinization, and stained
with propidium iodide (PI) following the manufacturer’s
instructions (Cayman Chemical). Cells were analyzed by
FACScan (BECKMAN COULTER) with MultiCycle for
Windows software (BECKMAN COULTER) for detailed
cell cycle status. The percentages of cells in G0/G1,S
and G2/M phases as well as those in any sub-G1 popula-
tion were determined from at least 20,000 ungated cells.
Coupled cell cycle and cell proliferation assay
A5 ’-bromo-2’-deoxyuridine (BrdU) flow kit (BD Phar-
mingen, San Diego, CA) was used to determine the cell
cycle kinetics and to measure the incorporation of BrdU
into DNA of proliferating cells. The assay was per-
formed according to the manufacturer’sp r o t o c o l .
Briefly, SBC5 cells (2 × 10
5 per well) were seeded over-
night in 6-well tissue culture plates and treated with an
optimized concentration of siRNAs in medium contain-
ing 10% FBS for 72 hours, followed by addition of 10
μM BrdU, and incubations continued for an additional
30 min. Both floating and adherent cells were pooled
from triplicates wells per treatment point, fixed in a
solution containing paraformaldehyde and the detergent
saponin, and incubated for 1 hour with DNase at 37°C
(30 μg per sample). FITC-conjugated anti-BrdU anti-
body (1:50 dilution in Wash buffer; BD Pharmingen,
San Diego, CA) was added and incubation continued for
20 minutes at room temperature. Cells were washed in
Wash buffer and total DNA was stained with 7-amino-
actinomycin D (7-AAD; 20 μL per sample), followed by
flow cytometric analysis using FACScan (BECKMAN
COULTER) and total DNA content (7-AAD) was deter-
mined CXP Analysis Software Ver. 2.2 (BECKMAN
COULTER).
Microarray hybridization and statistical analysis for the
clarification of down-stream genes
Purified total RNA was labeled and hybridized onto Affy-
metrix GeneChip U133 Plus 2.0 oligonucleotide arrays
(Affymetrix, Santa Clara, CA) according to the manufac-
turer’s instructions. Probe signal intensities were normal-
ized by RMA and Quantile normalization methods (using
R and Bioconductor). Next, signal intensity fluctuation
due to inter-experimental variation was estimated. Each
experiment was replicated (1 and 2), and the standard
deviation (stdev) of log2(intensity2/intensity1)w a sc a l c u -
lated for each of a set of intensity ranges with the mid-
points being at log2((intensity1+intensity2)/2) = 5, 7, 9, 11,
13, and 15. We modeled intensity variation using the for-
mula stdev(log2(intensity2/intensity1)) = a *( l o g 2((inten-
sity1+intensity2)/2)) + b and estimated parameters a and b
using the method of least squares. Using these values, the
standard deviation of intensity fluctuation was calculated.
The signal intensities of each probe were then compared
between siKDM5B (EXP) and controls (siEGFP/siFFLuc)
(CONT) and tested for up/down-regulation by calculating
the z-score: log2(intensityEXP/intensityCONT)/(a *( l o g 2
((intensityEXP+intensityCONT)/2)) + b). Resultant P-values
for the replication sets were multiplied to calculate the
final P-value of each probe. These procedures were applied
to each comparison: siEGFP vs. siKDM5B, siFFLuc vs.
siKDM5B, and siEGFP vs. siFFLuc, respectively. We deter-
mined up/down-regulated gene sets as those that simulta-
neously satisfied the following criteria: (1) The Benjamini-
Hochberg false discovery rate (FDR) < = 0.05 for siEGFP
vs. siKDM5B, (2) FDR < = 0.05 for siFFLuc vs. siKDM5B
and the regulation direction is the same as (1), and (3)
siEGFP vs. siFFLuc has the direction opposite to (1) and
(2) or P > 0.05 for siEGFP vs. siFFLuc. Finally, we per-
formed a pathway analysis using the hyper-geometric dis-
tribution test, which calculates the probability of overlap
between the up/down-regulated gene set and each GO
category compared against another gene list that is ran-
domly sampled. We applied the test to the identified up/
down-regulated genes to test whether or not they are sig-
nificantly enriched (FDR < = 0.05) in each category of
“Biological processes” (857 categories) as defined by the
Gene Ontology database.
E2F reporter assay
We analyzed the transcriptional activity of E2F by the
Cignal™ E2F Reporter Assay Kit (SuperArray Bioscience
Corporation). A549 and SBC5 cells were treated with
siRNAs (siEGFP and siKDM5B) and cultured for 24
hours. siRNA-treated cells were transfected with an
E2F-responsive luciferase construct, which encodes the
firefly luciferase reporter gene under the control of a
minimal (m)CMV promoter and tandem repeats of the
E2F transcriptional response element [TRE], negative
control or positive control. After 24 hours of transfec-
tion, dual luciferase assay was performed using Dual-
Luciferase Reporter Assay System (Promega), and
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using a Renilla reporter for internal normalization.
Experiments were done in triplicate, and Student’s
t-test was used for statistical analysis.
Additional file 1: Clinicopathologic characteristics and KDM5B
expression. Clinicopathologic information of bladder tumor tissues and
KDM5B expression analyzed by quantitative real-time PCR.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-59-
S1.PDF]
Additional file 2: Clinicopathologic characteristics of bladder tissues
on the tissue microarray. Clinicopathologic information of bladder
tumor tissues and KDM5B expression at the protein level.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-59-
S2.PDF]
Additional file 3: Clinicopathologic characteristics of lung tissues on
the tissue microarray. Clinicopathologic information of lung tumor
tissues and KDM5B expression at the protein level.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-59-
S3.PDF]
Additional file 4: Expression of KDM5B in cancer tissues analyzed
by cDNA microarray. Elevated KDM5B expression in AML, breast cancer,
CML, cervical cancer and renal cell carcinoma as well as bladder cancer
and lung cancer in Japanese populations.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-59-
S4.PDF]
Additional file 5: Elevated KDM5B expression in various types of
cancer. Elevated KDM5B expression in AML, breast cancer, CML, cervical
cancer and renal cell carcinoma in Japanese populations. Expression
levels of KDM5B were compared between normal and tumor tissues.
Signal intensity of each sample was analyzed by cDNA microarray, and
the result is shown by box-whisker plot (median 50% boxed). Mann-
Whitney’s U-test was used for statistical analysis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-59-
S5.PDF]
Additional file 6: Expression of KDM5B in cancer cell lines and FACS
analysis stained with BrdU and 7-AAD after siKDM5B treatment.( A )
Expression of KDM5B in 12 bladder cancer cell lines, in four non-small
cell lung cancer cell lines and one small cell lung cancer cell line. (B)
Effect of siKDM5B on cell cycle kinetics in SBC5 cells. Cell cycle
distribution was analyzed by flow cytometry after coupled staining with
fluorescein isothiocyanate (FITC)-conjugated anti-BrdU and 7-amino-
actinomycin D (7-AAD).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-59-
S6.PDF]
Additional file 7: Gene Ontology pathway analysis based on the
Affymetrix’s microarray data. Gene Ontology pathway analysis was
performed to clarify KDM5B functions in cancer cells.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-59-
S7.PDF]
Additional file 8: Two-dimensional, unsupervised hierarchical cluster
analysis of SW780 and A549 mRNA expression profiles after
knockdown of KDM5B expression. Differentially expressed genes were
selected for this analysis. Red, Up-regulated; Green, Down-regulated.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-59-
S8.PDF]
Additional file 9: Images of normal heart, kidney and liver stained
by standard immunohistochemistry for protein expression of
KDM5B. We performed the control staining without primary antibody to
eliminate the possibility of false-positive responses from the secondary
antibody, and counterstaining was done with hematoxylin and eosin.
Original magnification, ×40 and ×400.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-59-
S9.PDF]
Additional file 10: Subcellular localization of KDM5B in A549 cells.
A549 cells were subjected to cell cycle arrest by treatment with 7.5 μg/
ml aphidicolin for 24 hours then immunocytochemically stained using
anti-KDM5B monoclonal antibody (Alexa Fluor® 488 [green]), Phalloidin
(F-actin, Alexa Fluor® 594 [red]) and 4’,6’-diamidine-2’-phenylindole
dihydrochloride (DAPI; [blue]) at 0, 4, 8, 12 and 24 hours after aphidicolin
removal. Insets show FACS analysis demonstrating synchronized release
of cell cycle arrest. A549 cells were fixed with PBS (-) containing 4%
paraformaldehyde for 20 min, and rendered permeable with PBS (-)
containing 0.1% Triton X-100 at room temperature for 2 min.
Subsequently, the cells were covered with PBS (-) containing 3% bovine
serum albumin for 1 hour at room temperature to block non-specific
hybridization, and then were incubated with mouse anti-KDM5B
antibody (1G10, Abnova), diluted at 1:100 ratio dilution. After washing
with PBS (-), cells were stained by an Alexa Fluor® 488-conjugated anti-
mouse secondary antibody (Molecular Probes, OR, USA) at 1:1000
dilution. Nuclei were counter-stained with 4’,6’-diamidine-2’-phenylindole
dihydrochloride (DAPI). Fluorescent images were obtained under a TCS
SP2 AOBS microscope (Leica).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-59-
S10.PDF]
Additional file 11: Subcellular localization of KDM5B in SBC5 cells.
Same assay as Additional file 11, but using SBC5 cells.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-59-
S11.PDF]
Additional file 12: Primer sequences for quantitative RT-PCR. Specific
primer sequence for GAPDH (housekeeping gene), SDH (housekeeping
gene), KDM5B, E2F1 and E2F2, respectively.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-59-
S12.PDF]
Additional file 13: siRNA sequences. Sequences of siEGFP, siFFLuc,
siNC (negative control), and siKDM5B, respectively.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-59-
S13.PDF]
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